Navigation Links
Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Date:9/4/2007

CORONA, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received its first U.S. Food and Drug Administration (FDA) product approval at its Goa, India facility. During the next several months the company plans to seek FDA approval to manufacture additional solid dosage products at the facility. By early 2008, the Goa facility is expected to be producing over 1 billion tablets and capsules annually for the U.S. market.

"This approval represents a key milestone for Watson, demonstrating our rapid progress toward building an offshore infrastructure," said Allen Chao, Ph.D., Watson's Executive Chairman. "In the coming months we anticipate making additional FDA submissions to transfer certain products to this facility to achieve efficiencies in scale and cost. This will enhance our ability to provide quality, low cost generic pharmaceutical products to the U.S. marketplace."

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, difficulties or delays in transferring product manufacturing to the Goa facility; difficulties or delays in obtaining U.S. Food and Drug Administration or other regulatory approvals to manufacture products at the Goa, India site for the U.S. market; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Pravastatin Launched by Watson Pharmaceuticals
3. Watson Amazed by Radcliffes Steamy Shots
4. Infant receives first bloodless liver transplant
5. Fifth US Patient Receives Artificial Heart
6. Northfield Labs Receives FDA Comments
7. British MPs Say Prostate Cancer Receives Low Priority in the NHS
8. Abbott Receives CE Mark Certification
9. Zactima Receives Fast Track Designation By The FDA
10. East London Receives World Class New Private Hospital Facility
11. Brinda Karat Receives Legal Notice over Ramdev Issue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2018)... ... August 14, 2018 , ... Gastro Health, LLC (“Gastro ... for healthcare executives Simon Frisch and Chris Weinstein, who have been appointed Senior ... roles at a time of tremendous growth for the group, which has increased ...
(Date:8/14/2018)... ... August 14, 2018 , ... Eagle ... Group, a leading provider of residential and commercial recreational surfacing products across the ... industry, with products used across a wide range of markets and customers. Founded ...
(Date:8/11/2018)... OVERLAND PARK, Kan. (PRWEB) , ... August 10, ... ... Gout Gone, an industry leader in Gout Relief. , What is gout? This ... the lower extremities as a result of high levels of uric acid. Other ...
(Date:8/11/2018)... (PRWEB) , ... August 11, 2018 , ... ... of a Silver Stevie® Award in the Executive of the Year-Business category in ... world’s premier business awards program. All individuals and organizations worldwide – public and ...
(Date:8/9/2018)... ... August 09, 2018 , ... Balboa Horizons, an industry ... process that substance abuse providers must pass in order to advertise on Google. ... people to help.” , Helping people is what Balboa Horizons is all ...
Breaking Medicine News(10 mins):
(Date:8/11/2018)... SAN FRANCISCO (PRWEB) , ... August 10, 2018 , ... ... round financial advisor, following a $2 million seed funding round. Carepoynt is an emerging ... consumers at the center of a more rewarding and engaging healthcare ecosystem. , Headquartered ...
(Date:8/11/2018)... ... August 11, 2018 , ... ... of ‘Information Matrix’ on integrative medicine. The episode will go through different integrative ... society. , Integrative medicine involves using both conventional and complementary approaches to health ...
(Date:8/9/2018)... ... 2018 , ... Doctor Snehal Patel is offering the residents of South Fairfax ... September 30th, applicants who are in need of full-arch restorations, but who otherwise couldn’t ... Project Smile Program. , "Our local communities have been very good to us and ...
Breaking Medicine Technology: